Maggiolo F - Search Results

1

High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.

Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. Fabbiani M, et al. Among authors: maggiolo f. J Viral Hepat. 2021 Mar;28(3):558-568. doi: 10.1111/jvh.13454. Epub 2021 Jan 2. J Viral Hepat. 2021. PMID: 33306247

2

Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.

Clerici M, Seminari E, Suter F, Castelli F, Pan A, Biasin M, Colombo F, Trabattoni D, Maggiolo F, Carosi G, Maserati R. Clerici M, et al. Among authors: maggiolo f. AIDS. 2000 Jan 28;14(2):109-16. doi: 10.1097/00002030-200001280-00005. AIDS. 2000. PMID: 10708280

3

Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.

Paolucci S, Baldanti F, Maserati R, Castelli F, Suter F, Maggiolo F, Pan A, Gerna G. Paolucci S, et al. Among authors: maggiolo f. Antiviral Res. 2000 Feb;45(2):101-14. doi: 10.1016/s0166-3542(00)00062-0. Antiviral Res. 2000. PMID: 10809019

4

Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients.

Baldanti F, Paolucci S, Maserati R, Maggiolo F, Pan A, Castelli F, Gulminetti R, Comolli G, Chiesa A, Gerna G. Baldanti F, et al. Among authors: maggiolo f. Eur J Clin Microbiol Infect Dis. 2000 May;19(5):380-4. doi: 10.1007/s100960050499. Eur J Clin Microbiol Infect Dis. 2000. PMID: 10898142

5

Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients.

Clerici M, Seminari E, Maggiolo F, Pan A, Migliorino M, Trabattoni D, Castelli F, Suter F, Fusi ML, Minoli L, Carosi G, Maserati R; Master Group. Clerici M, et al. Among authors: maggiolo f. AIDS. 2002 Sep 6;16(13):1767-73. doi: 10.1097/00002030-200209060-00009. AIDS. 2002. PMID: 12218388

6

Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.

Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'Aquila R, Lisziewicz J, Lori F. Foli A, et al. Among authors: maggiolo f. Antivir Ther. 2004 Feb;9(1):123-32. Antivir Ther. 2004. PMID: 15040544 Clinical Trial.

7

A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.

Puoti M, Zanini B, Quinzan GP, Ravasio L, Paraninfo G, Santantonio T, Rollo A, Artioli S, Maggiolo F, Zaltron S, Raise E, Mignani E, Resta F, Verucchi G, Pastore G, Suter F, Carosi G; MASTER HIV/HCV Co-Infection Study Group. Puoti M, et al. Among authors: maggiolo f. J Hepatol. 2004 Aug;41(2):312-8. doi: 10.1016/j.jhep.2004.04.016. J Hepatol. 2004. PMID: 15288482 Free PMC article. Clinical Trial.

8

Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.

Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Morsica G, et al. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592. J Acquir Immune Defic Syndr. 2009. PMID: 19590432

9

Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.

d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group. d'Arminio Monforte A, et al. Among authors: maggiolo f. Clin Infect Dis. 2009 Aug 15;49(4):612-22. doi: 10.1086/603557. Clin Infect Dis. 2009. PMID: 19591597

10

One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects.

Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, Bai F, Orofino G, Sighinolfi L, Gori A, Suter F, Maggiolo F. Airoldi M, et al. Among authors: maggiolo f. Patient Prefer Adherence. 2010 May 13;4:115-25. doi: 10.2147/ppa.s10330. Patient Prefer Adherence. 2010. PMID: 20517472 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

337 results

Search Page